Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Efficacy of Disease-Modifying Treatments in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Five Phase III Randomized Controlled Trials. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.jacc.2022.11.022
10.1016/j.jacc.2022.11.022 · External reference
10.1093/eurheartj/ehab072
10.1093/eurheartj/ehab072 · External reference
Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis
2023 · External reference
10.1253/circj.cj-20-0110
10.1253/circj.cj-20-0110 · External reference
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
10.1001/jamacardio.2021.3070 · 2021 · External reference
Prevalence of Transthyretin Amyloidosis Among Heart Failure Patients with Preserved Ejection Fraction in Japan
10.1002/ehf2.14364 · 2023 · External reference
10.1001/jama.2024.0442
10.1001/jama.2024.0442 · External reference
10.1161/circulationaha.118.038169
10.1161/circulationaha.118.038169 · External reference
10.1001/jama.2020.5493
10.1001/jama.2020.5493 · External reference
The Last Decade in Cardiac Amyloidosis
10.1016/j.jcmg.2024.10.011 · 2025 · External reference
Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study
2023 · External reference
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects
10.1007/s00259-025-07079-4 · 2025 · External reference
Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy
10.1016/j.jfma.2024.10.005 · 2025 · External reference
Long-Term Impact of Eplontersen on Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Ala97Ser Hereditary Transthyretin Amyloid Cardiomyopathy
2026 · External reference
10.1056/nejmoa1805689
10.1056/nejmoa1805689 · External reference
10.1056/nejmoa2300757
10.1056/nejmoa2300757 · External reference
10.1056/nejmoa2305434
10.1056/nejmoa2305434 · External reference
10.1056/nejmoa2409134
10.1056/nejmoa2409134 · External reference
10.1056/nejmoa2608510
10.1056/nejmoa2608510 · External reference
10.1056/nejmoa2303765
10.1056/nejmoa2303765 · External reference
10.1161/circulationaha.125.077304
10.1161/circulationaha.125.077304 · External reference
10.1016/j.cardfail.2025.08.002
10.1016/j.cardfail.2025.08.002 · External reference
10.1001/jama.2026.17246
10.1001/jama.2026.17246 · External reference
Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis
2025 · External reference
10.1161/circulationaha.119.045093
10.1161/circulationaha.119.045093 · External reference
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy
10.1016/j.jacc.2026.07.022 · 2026 · External reference
10.1038/s41591-026-04670-6
10.1038/s41591-026-04670-6 · External reference
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
10.1016/j.jacc.2024.03.429 · 2024 · External reference
SGLT2 Inhibitor Therapy for Transthyretin Amyloid Cardiomyopathy: Early Tolerance and Clinical Response to Dapagliflozin
10.1002/ehf2.14188 · 2023 · External reference
Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis
10.1111/eci.14392 · 2025 · External reference
